Current FDA labels document these patterns in detail: Wegovy (semaglutide) lists nausea (44% vs 16% placebo), vomiting (25% vs 6%), diarrhea (30% vs 16%), constipation (24% vs 11%), abdominal distension and eructation, with severe GI events in 4.1% versus 0.9% placebo.[2] Zepbound (tirzepatide) lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, eructation, and gastroesophageal reflux disease among common adverse reactions, with severe GI disease as a Warnings and Precautions item.[3] Both labels include postmarketing reports of ileus, severe constipation including fecal impaction, and acute kidney injury related to dehydration from severe GI symptoms
Sleep, circadian rhythms and health
Furthermore, multistrain protocols, including Saccharomyces boulardii and Lactobacillus acidophilus , have demonstrated reductions in fatigue and improvements in cognition and mood (Stallmach et al., 2024)
Christoff AP, Fernanda A, Sereia R, et al (2017) White paper: Bacterial NGS sequencing neoprospecta microbiome technologies bacterial identification through accurate library preparation and high-throughput sequencing
California'da oran yzde 9,5, Washington ve Nevada'da ise yzde 8-9 bandnda seyrediyor
Side Effects and Safety Considerations While generally well-tolerated, Semaglutide may cause side effects such as nausea, vomiting, and diarrhea, particularly during the initial stages of treatment
